First oral therapies for multiple sclerosis anticipated.
Hughes
Bethan
B
D000284:Administration, Oral; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000503:physiopathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000503:physiopathology
D007166:Immunosuppressive Agents